Department of Microbiology and Tumor Virology, University of Pennsylvania School of Medicine, Philadelphia, USA.
Cancer Biol Ther. 2010 Nov 15;10(10):961-78. doi: 10.4161/cbt.10.10.13923.
Tumor viruses have provided relatively simple genetic systems, which can be manipulated for understanding the molecular mechanisms of the cellular transformation process. A growing body of information in the tumor virology field provides several prospects for rationally targeted therapies. However, further research is needed to better understand the multiple mechanisms utilized by these viruses in cancer progression in order to develop therapeutic strategies. Initially viruses were believed to be associated with cancers as causative agents only in animals. It was almost half a century before the first human tumor virus, Epstein-Barr virus (EBV), was identified in 1964. Subsequently, several human tumor viruses have been identified including Kaposi sarcoma associated herpesvirus (KSHV), human Papillomaviruses (HPV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T lymphotropic virus (HTLV-1) and recently identified Merkel cell Polyomavirus (MCPyV). Tumor viruses are sub-categorized as either DNA viruses, which include EBV, KSHV, HPV, HBV, and MCPyV, or RNA viruses such as HCV and HTLV-1. Tumor-viruses induce oncogenesis through manipulating an array of different cellular pathways. These viruses initiate a series of cellular events, which lead to immortalization and proliferation of the infected cells by disrupting the mitotic checkpoint upon infection of the host cell. This is often accomplished by functional inhibition or proteasomal degradation of many tumor suppressor proteins by virally encoded gene products. The virally infected cells can either be eliminated via cell-mediated apoptosis or persist in a state of chronic infection. Importantly, the chronic persistence of infection by tumor viruses can lead to oncogenesis. This review discusses the major human tumor associated viruses and their ability to modulate numerous cell signaling pathways, which can be targeted for potential therapeutic approaches.
肿瘤病毒提供了相对简单的遗传系统,可以对其进行操作以了解细胞转化过程的分子机制。肿瘤病毒学领域不断增加的信息为合理靶向治疗提供了几个前景。但是,为了开发治疗策略,需要进一步研究这些病毒在癌症进展中利用的多种机制,以更好地了解它们。最初,人们认为病毒仅作为动物癌症的病原体。直到 1964 年才发现第一种人类肿瘤病毒,即 Epstein-Barr 病毒(EBV),这已经过去了将近半个世纪。随后,已经鉴定出几种人类肿瘤病毒,包括卡波西肉瘤相关疱疹病毒(KSHV),人乳头瘤病毒(HPV),乙型肝炎病毒(HBV),丙型肝炎病毒(HCV),人类 T 淋巴细胞病毒(HTLV-1)和最近发现的 Merkel 细胞多瘤病毒(MCPyV)。肿瘤病毒分为 DNA 病毒,包括 EBV、KSHV、HPV、HBV 和 MCPyV,或 RNA 病毒,如 HCV 和 HTLV-1。肿瘤病毒通过操纵一系列不同的细胞途径来诱导癌变。这些病毒引发一系列细胞事件,通过在感染宿主细胞时破坏有丝分裂检查点,导致受感染细胞的永生化和增殖。这通常通过病毒编码基因产物的功能抑制或蛋白酶体降解许多肿瘤抑制蛋白来完成。受病毒感染的细胞可以通过细胞介导的细胞凋亡消除,也可以持续处于慢性感染状态。重要的是,肿瘤病毒的慢性持续感染会导致癌变。本文讨论了主要的人类肿瘤相关病毒及其调节多种细胞信号通路的能力,这些通路可作为潜在治疗方法的靶点。